Home › Compare › REMRF vs ABBV
REMRF yields 398.88% · ABBV yields 3.06%● Live data
📍 REMRF pulled ahead of the other in Year 1
Combined, REMRF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of REMRF + ABBV for your $10,000?
Atlas Salt Inc., a junior mineral exploration company, engages in the acquisition, evaluation, and exploration of mineral properties in Newfoundland and Labrador, Canada. The company explores for potash, salt, gypsum, and other mineral deposits. It holds 100% interest in the Great Atlantic salt project in the Bay St. George Basin of Western Newfoundland. The company also holds interests in the Ace Gypsum project located in the dormant Flat Bay gypsum mines to the southwest of the Great Atlantic salt deposit; and the Black Bay Nepheline property located in southern Labrador. As of December 31, 2021, the company had 30 mineral licenses approximately 21,725 hectares in the Bay St. George region of Western Newfoundland and in Black Bay, Labrador. The company was formerly known as Red Moon Resources Inc. and changed its name to Atlas Salt Inc. in August 2021. Atlas Salt Inc. was incorporated in 2011 and is headquartered in St. John's, Canada.
Full REMRF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.